Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Active Motif, Golden Helix, Variantyx

Active Motif CUT&RUN Assay and Epigenetic Services

Active Motif of Carlsbad, California has launched a CUT&RUN assay kit and End-to-End Epigenetics Services for CUT&RUN analysis. CUT&RUN (cleavage under targets and release using nuclease) is a sensitive and specific method for identifying genome-wide binding patterns of chromatin-associated proteins such as transcription factors or histone modifications, the company said. Chromatin-associated proteins play critical roles in regulating various cellular processes such as gene expression, DNA replication, DNA repair, and cell differentiation, and understanding their binding patterns can provide insight into the regulation of these cellular processes, Active Motif said.

Golden Helix VarSeq 2.5.0, Cancer KB 3.0

Golden Helix has released VarSeq 2.5.0. The new version features an advanced oncogenicity classifier algorithm that reduces manual work involved in assessing a variant's oncogenicity. It also now supports a carrier screening workflow from data import to clinical report, generating reports that contain variants from both prospective parents and their computed reproductive risk. In addition, the firm has launched Golden Helix Cancer KB 3.0. The updated database contains expert-curated interpretations of biomarkers and therapeutic evidence.

Variantyx Expanded Genomic Unity Test

Variantyx has expanded the set of short tandem repeat expansions detected by its Genomic Unity line of whole-genome analysis tests, adding two recently characterized ataxia variants: the biallelic AAGGG expansion in RFC1 that causes cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS); and the monoallelic, deep intronic GAA expansion in FGF14 that causes spinocerebellar ataxia 27B (SCA27B). Genomic Unity now analyzes 37 repeat expansions, collectively enabling the genetic diagnosis of late-onset neuropathies, neuromuscular disorders, and movement disorders — particularly ataxias — as well as early-onset disorders, including those with symptoms of epilepsy and intellectual disability, the Framingham, Massachusetts-based company said.

For more new products and services, please visit the New Products page on our website.